July 10, 2025 06:34 AM EDT
R&D

Ul­tragenyx, Mereo’s bone dis­ease drug fails sec­ond in­ter­im analy­sis, stocks plum­met

Elizabeth Cairns

Senior biopharma journalist

Ul­tragenyx Phar­ma­ceu­ti­cal and Mereo Bio­Phar­ma’s an­ti­body for a rare bone dis­ease failed a sec­ond in­ter­im analy­sis in its piv­otal tri­al, the com­pa­nies

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: FDA pub­lish­es repos­i­to­ry of 200+ drug re­jec­tion let­ters, promis­ing more in the fu­ture

Ab­b­Vie inks $700M deal with IGI for mul­ti­ple myelo­ma trispe­cif­ic an­ti­body

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

Who pays the most in bio­phar­ma? We an­a­lyzed me­di­an pay at 177 com­pa­nies

Kid­ney health biotech emerges with $54M to fol­low in Ver­tex’s foot­steps

sponsored

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

A service from the Financial Times